Phase II study of weekly irinotecan (CPT-11) as second-line treatment of patients with advanced colorectal cancer

By Cassinello J.   López-Alvarez P.   Martínez-Guisado A.   Valladares M.   Huidobro G.   López R.   Bohn U.   Sevilla I.   Ballesteros P.   Jorge M.   Pérez-Carrión R.   Fernández J.   Dorta J.  

Medical Oncology, Vol. 20, Iss. 1, 2003-03 ,pp. : 37-43

Humana Press, Inc

Access to resources Recommend Favorite

Phase I study of bevacizumab combined with irinotecan and S-1 as second-line chemotherapy in patients with advanced colorectal cancer

By Kusaba Hitoshi   Esaki Taito   Kishimoto Junji   Uchino Keita   Arita Shuji   Kumagai Hozumi   Mitsugi Kenji   Akashi Koichi   Baba Eishi  

Cancer Chemotherapy and Pharmacology, Vol. 71, Iss. 1, 2013-01 ,pp. : 29-34

Springer Publishing Company

Access to resources Recommend Favorite

Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer

By  

Cancer Medicine, Vol. 2045-7634, Iss. 10, 2015-10 ,pp. : 1505-1513

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase II trial of weekly fractionated irinotecan and cisplatin for advanced gastric cancer

By Jeung Hei-Cheul   Rha Sun   Noh Sung   Roh Jae   Chung Hyun  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 3, 2007-03 ,pp. : 313-320

Springer Publishing Company

Access to resources Recommend Favorite

Phase I clinical trial of a peptide vaccine combined with tegafur-uracil plus leucovorin for treatment of advanced or recurrent colorectal cancer

By            

Oncology Reports, Vol. 29, Iss. 3, 2013-01 ,pp. : 951-959

Spandidos Publications

Access to resources Recommend Favorite